Skip to main content
SpringerLink
Log in

Targeted Therapy in Chronic Myeloid Leukemia

  • Chapter
Targeted Cancer Therapy

Part of the book series: Current Clinical Oncology™ ((CCO))

  • 1046 Accesses

Abstract

The successful introduction of the tyrosine kinase inhibitors (TKIs) has revolutionized the outcome of patients with chronic myeloid leukemia (CML). Imatinib mesylate therapy induced high rates of complete cytogenetic and major molecular responses and improved survival for patients with CML. A small proportion of patients in chronic phase CML and more patients in advanced phases are resistant to imatinib or develop resistance during treatment through BCR-ABL-dependent and BCR-ABL-independent mechanisms. Novel, more potent TKIs can overcome imatinib resistance, including dasatinib (a potent dual Src and Bcr-Abl inhibitor), nilotinib (a selective potent Bcr-Abl inhibitor), bosutinib and INNO406 (both Src-Abl inhibitors), among others. Other approaches are exploring combination therapy, agents affecting various oncogenic pathways, and immune modulation. This chapter reviews some of these targeted therapies, particularly those for which clinical data are already available.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106–30.

    PubMed  Google Scholar 

  2. Faderl S, Talpaz M, Estrov Z, et al. The biology of chronic myeloid leukemia. N Engl J Med 1999;341:164–72.

    Article  PubMed  CAS  Google Scholar 

  3. Goldman JM, Melo JV. Chronic myeloid leukemia—advances in biology and new approaches to treatment. N Engl J Med 2003;349:1451–64.

    Article  PubMed  CAS  Google Scholar 

  4. Lionberger JM, Wilson MB, Smithgall TE. Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck. J Biol Chem 2000;275:18581–5.

    Article  PubMed  CAS  Google Scholar 

  5. Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003;101:690–8.

    Article  PubMed  CAS  Google Scholar 

  6. Dai Y, Rahmani M, Corey SJ, et al. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 2004;279:34227–39.

    Article  PubMed  CAS  Google Scholar 

  7. Faderl S, Kantarjian HM, Talpaz M. Chronic myelogenous leukemia: update on biology and treatment. Oncology (Williston Park) 1999;13:169–80.

    CAS  Google Scholar 

  8. Chronic Myeloid Leukemia Trialists’ Collaborative Group. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst 1997;89:1616–20.

    Article  Google Scholar 

  9. Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med 1997;337:223–9.

    Article  PubMed  CAS  Google Scholar 

  10. Kantarjian HM, O’Brien S, Smith TL, et al. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. J Clin Oncol 1999;17:284–92.

    PubMed  CAS  Google Scholar 

  11. Hehlmann R, Pfirrmann M, Hochhaus A, et al. Randomized comparison of primary allogeneic stem cell transplantation and best available drug treatment in chronic myeloid leukemia. Blood 2006;108:427.

    Google Scholar 

  12. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645–52.

    Article  PubMed  CAS  Google Scholar 

  13. Kantarjian HM, Cortes JE, O’Brien S, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-α. Blood 2004;104:1979–88.

    Article  PubMed  CAS  Google Scholar 

  14. O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994–1004.

    Article  PubMed  CAS  Google Scholar 

  15. Kantarjian H, Talpaz M, O’Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004;103:2873–8.

    Article  PubMed  CAS  Google Scholar 

  16. Cortes J, Talpaz M, O’Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005;11:3425–32.

    Article  PubMed  CAS  Google Scholar 

  17. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423–32.

    Article  PubMed  CAS  Google Scholar 

  18. Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002;16:2190–6.

    Article  PubMed  CAS  Google Scholar 

  19. Gambacorti-Passerini CB, Gunby RH, Piazza R, et al. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003;4:75–85.

    Article  PubMed  Google Scholar 

  20. Jabbour E, Cortes J, Giles F, et al. Current and emerging treatment options in chronic myeloid leukemia. Cancer 2007;109:2171–81.

    Article  PubMed  CAS  Google Scholar 

  21. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561–6.

    Article  PubMed  CAS  Google Scholar 

  22. Beran M, Cao X, Estrov Z, et al. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res 1998 ;4:1661–72.

    PubMed  CAS  Google Scholar 

  23. Kantarjian HM, Cortes JE, O’Brien S, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood 2003;101:97–100.

    Article  PubMed  CAS  Google Scholar 

  24. Druker BJ, Guilhot F, O’Brien S, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408–17.

    Article  PubMed  CAS  Google Scholar 

  25. Kantarjian HM, Talpaz M, O’Brien S, et al. Survival benefit with imatinib mesylate versus interferon-α-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 2006;108:1835–40.

    Article  PubMed  CAS  Google Scholar 

  26. Roy L, Guilhot J, Krahnke T, et al. Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 2006;108:1478–84.

    Article  PubMed  CAS  Google Scholar 

  27. Gambacorti-Passerini C, Talpaz M, Sawyers C, et al. Five year follow-up results of a phase II trial in patients with late chronic phase CML treated with imatinib who are refractory/intolerant to interferon alfa. Blood 2005;107:317a.

    Google Scholar 

  28. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99:3530–9.

    Article  PubMed  CAS  Google Scholar 

  29. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99:1928–37.

    Article  PubMed  CAS  Google Scholar 

  30. Silver RT, Talpaz M, Sawyers CL, et al. Four years of follow-up of 1027 patients with late chronic phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials. Blood 2004;104:11a.

    Article  CAS  Google Scholar 

  31. Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908–16.

    Article  PubMed  CAS  Google Scholar 

  32. Atallah E, Durand JB, Kantarjian H, et al. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2006;108. Abstract 246.

    Google Scholar 

  33. Peng B, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004;22:935–42.

    Article  PubMed  CAS  Google Scholar 

  34. Schmidli H, Peng B, Riviere GJ, et al. Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study. Br J Clin Pharmacol 2005;60:35–44.

    Article  PubMed  CAS  Google Scholar 

  35. Cortes J, Giles F, O’Brien S, et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-α. Blood 2003;102:83–6.

    Article  PubMed  CAS  Google Scholar 

  36. Kantarjian H, Talpaz M, O’Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003;101:473–5.

    Article  PubMed  CAS  Google Scholar 

  37. Hughes TP, Branford S, Matthews J, et al. Trial of higher dose imatinib with selective intensification in newly diagnosed CML patients in chronic phase. Blood 2003:102:31a.

    Article  CAS  Google Scholar 

  38. Cortes J, Giles F, Salvado A, et al. High-dose (HD) imatinib in patients with previously untreated chronic myeloid leukemia (CML) in early chronic phase (CP): preliminary results of a multicenter community based trial. J Clin Oncol 2005; 23:564a.

    Article  CAS  Google Scholar 

  39. Rosti G, Martinelli G, Castagnetti F, et al. Imatinib 800 mg: preliminary results of a phase II trial of the GIMEMA CML working party in intermediate Sokal risk patients and status-of-the-art of an ongoing multinational, prospective randomized trial of imatinib standard dose (400 mg daily) is high dose (800 mg daily) in high Sokal risk patients. Blood 2005; 106:320a.

    Google Scholar 

  40. Aoki E, Kantarjian H, O’Brien S, et al. High-dose (HD) imatinib provides better responses in patients with untreated early chronic phase (CP) chronic myeloid leukemia (CML). Blood 2006;108. Abstract 2143.

    Google Scholar 

  41. Hughes TP, Deininger MW, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28–37.

    Article  PubMed  CAS  Google Scholar 

  42. Shah NP. Loss of response to imatinib: mechanisms and management. Hematology Am Soc Hematol Educ Program 2005;183–7.

    Google Scholar 

  43. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876–80.

    Article  PubMed  CAS  Google Scholar 

  44. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003;102:276–83.

    Article  PubMed  CAS  Google Scholar 

  45. Jabbour E, Kantarjian H, Jones D, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006;20:1767–73.

    Article  PubMed  CAS  Google Scholar 

  46. Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005;23:4100–9.

    Article  PubMed  CAS  Google Scholar 

  47. Nicolini FE, Corm S, Le QH, et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(varphi)-LMC Group). Leukemia 2006;20:1061–6.

    Article  PubMed  CAS  Google Scholar 

  48. Von Bubnoff N, Schneller F, Peschel C, et al. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002;359:487–91.

    Article  Google Scholar 

  49. Corbin AS, Buchdunger E, Pascal F, et al. Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. J Biol Chem 2002;277:32214–9.

    Article  PubMed  CAS  Google Scholar 

  50. Azam M, Latek RR, Daley GQ, et al. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003;112:831–43.

    Article  PubMed  CAS  Google Scholar 

  51. Gambacorti-Passerini C, Zucchetti M, Russo D, et al. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 2003;9:625–32.

    PubMed  CAS  Google Scholar 

  52. Donato NJ, Wu JY, Stapley J, et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 2004; 64:672–7.

    Article  PubMed  CAS  Google Scholar 

  53. Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003;101:690–8.

    Article  PubMed  CAS  Google Scholar 

  54. Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399–401.

    Article  PubMed  CAS  Google Scholar 

  55. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531–41.

    Article  PubMed  CAS  Google Scholar 

  56. Baccarani M, Kantarjian HM, Apperley JF, et al. Efficacy of dasatinib (SPRYCEL) in patients (pts) with chronic phase chronic myelogenous leukemia (CP-CML) resistant to or intolerant of imatinib: updated results of the CA180013 START-C phase II study. Blood 2006;108. Abstract 164.

    Google Scholar 

  57. Shah N, Pasquini R, Rousselot P, et al. Dasatinib (SPRYCEL) vs escalated dose of imatinib (im) in patients (pts) with chronic phase chronic myeloid leukemia (CP-CML) resistant to imatinib: results of the CA180–017 START-R randomized study. Blood 2006;108. Abstract 167.

    Google Scholar 

  58. Cortes J, Kim DW, Guilhot F, et al. Dasatinib (SPRYCEL) in patients (pts) with chronic myelogenous leukemia in accelerated phase (AP-CML) that is imatinib-resistant (im-r) or -intolerant (im-i): updated results of the CA180–005 START-A phase II study. Blood 2006;108. Abstract 2160.

    Google Scholar 

  59. Martinelli G, Hochhaus A, Coutre S, et al. Dasatinib (SPRYCEL) efficacy and safety in patients (pts) with chronic myelogenous leukemia in lymphoid (CML-LB) or myeloid blast (CML-MB) phase who are imatinib-resistant (im-r) or -intolerant (im-i). Blood 2006;108. Abstract 745.

    Google Scholar 

  60. Dombret H, Ottman OG, Rosti G, et al. Dasatinib (SPRYCEL) in patients (pts) with Philadelphia chromosome-positive acute lymphoblastic leukemia who are imatinib-resistant (im-r) or -intolerant (im-i): updated results from the CA180–015 START-L study. Blood 2006;108. Abstract 286.

    Google Scholar 

  61. Hochhaus A, Kim DW, Rousselot P, et al. Dasatinib (SPRYCEL®) 50mg or 70mg BID Versus 100mg or 140mg qd in patients with chronic myeloid leukemia in chronic phase (CML-CP) resistant or intolerant to imatinib: results of the CA180–034 study. Blood 2006;108. Abstract 166.

    Google Scholar 

  62. Kantarjian H, Ottmann O, Pasquini R, et al. Dasatinib (®) 140 mg once daily (qd) vs 70 mg twice daily (bid) in patients (pts) with advanced phase chronic myeloid leukemia (ABP-CML) or Ph(+) ALL who are resistant or intolerant to imatinib (im): results of the CA180–035 study. Blood 2006;108.Abstract 746.

    Google Scholar 

  63. Cortes J, O’Brien S, Jones D, et al. Dasatinib in patients with previously untreated chronic myeloid leukemia in chronic phase. Blood 2006;108. Abstract 2161.

    Google Scholar 

  64. O’Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500–5.

    Article  PubMed  CAS  Google Scholar 

  65. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129–41.

    Article  PubMed  CAS  Google Scholar 

  66. Verstovsek S, Golemovic M, Kantarjian H, et al. AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer 2005;104:1230–6.

    Article  PubMed  CAS  Google Scholar 

  67. Jensen MR, Bruggen J, DiLea C, et al. AMN107: efficacy of the selective Bcr-Abl tyrosine kinase inhibitor in a murine model of chronic myelogenous leukemia. Proc Am Assoc Cancer Res 2006;47. Abstract 261.

    Google Scholar 

  68. Weisberg E, Manley P, Mestan J, et al. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 2006;94:1765–9.

    Article  PubMed  CAS  Google Scholar 

  69. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2542–51.

    Article  PubMed  Google Scholar 

  70. Le Coutre P, Bhalla K, Giles F, et al. A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib-resistant and -intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP). Blood 2006;108. Abstract 165.

    Google Scholar 

  71. Kantarjian HM, Gattermann N, Hochhaus A, et al. A phase II study of nilotinib a novel tyrosine kinase inhibitor administered to imatinib-resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP). Blood 2006;108. Abstract 2169.

    Google Scholar 

  72. Ottmann O, Kantarjian H, Larson R, et al. A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL). Blood 2006;108. Abstract 1862.

    Google Scholar 

  73. Jabbour E, Cortes J, Giles F, et al. Preliminary activity of AMN107, a novel potent oral selective Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukaemia (CML-CP). Blood 2006;108. Abstract 2172.

    Google Scholar 

  74. Cortes J, Kantarjian HM, Baccarani M, et al. A phase 1/2 study of SKI-606, a dual Inhibitor of Src and Abl kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory or intolerant of imatinib. Blood 2006;108. Abstract 168.

    Google Scholar 

  75. Craig AR, Kantarjian HM, Cortes JE, et al. Phase I study of INNO-406, a dual inhibitor of Abl and Lyn kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory, or intolerant of imatinib. J Clin Oncol 2007; Abstract 7046.

    Google Scholar 

  76. Giles FJ, Cortes JE, Jones D, et al. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007;109:500–2.

    Article  PubMed  CAS  Google Scholar 

  77. Cortes J, Albitar M, Thomas D, et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 2003;101:1692–7.

    Article  PubMed  CAS  Google Scholar 

  78. Issa JP, Gharibyan V, Cortes J, et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 2005;23:3948–56.

    Article  PubMed  CAS  Google Scholar 

  79. Marin D, Kaeda JS, Andreasson C, et al. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. Cancer 2005;103:1850–5.

    Article  PubMed  CAS  Google Scholar 

  80. Pinilla-Ibarz J, Cathcart K, Scheinberg DA. CML vaccines as a paradigm of the specific immunotherapy of cancer. Blood Rev 2000;14:111–20.

    Article  PubMed  CAS  Google Scholar 

  81. Quintas-Cardama A, Cortes J. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc 2006;81:973–88.

    Article  PubMed  CAS  Google Scholar 

  82. Cathcart K, Pinilla-Ibarz J, Korontsvit T, et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 2004;103:1037–42.

    Article  PubMed  CAS  Google Scholar 

  83. Bocchia M, Gentili S, Abruzzese E, et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicenter observational trial. Lancet 2005;365:657–62.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Elias Jabbour MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jorge Cortes MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hagop Kantarjian MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Investigational Cancer Therapeutics Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

    Razelle Kurzrock MD

  2. Department of Clinical Research, The University of Texas MD Anderson Cancer Center, Houston, TX

    Maurie Markman

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, Totowa, NJ

About this chapter

Cite this chapter

Jabbour, E., Cortes, J., Kantarjian, H. (2008). Targeted Therapy in Chronic Myeloid Leukemia. In: Kurzrock, R., Markman, M. (eds) Targeted Cancer Therapy. Current Clinical Oncology™. Humana Press. https://doi.org/10.1007/978-1-60327-424-1_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-424-1_5

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60327-423-4

  • Online ISBN: 978-1-60327-424-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation